These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1342 related items for PubMed ID: 29412075

  • 21. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
    Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C.
    High Blood Press Cardiovasc Prev; 2019 Jun; 26(3):199-207. PubMed ID: 31236902
    [Abstract] [Full Text] [Related]

  • 22. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

  • 23. LDL cholesterol: How low to go?
    Packard CJ.
    Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Poststatin Lipid Therapeutics: A Review.
    Jia X, Lorenz P, Ballantyne CM.
    Methodist Debakey Cardiovasc J; 2019 Jul; 15(1):32-38. PubMed ID: 31049147
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J.
    Curr Atheroscler Rep; 2019 Mar 16; 21(5):16. PubMed ID: 30877491
    [Abstract] [Full Text] [Related]

  • 29. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA, Elshourbagy NA, Mousa SA.
    Pharmacol Ther; 2016 Aug 16; 164():183-94. PubMed ID: 27133571
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
    Noto D, Giammanco A, Barbagallo CM, Cefalù AB, Averna MR.
    Cardiovasc Res; 2018 Oct 01; 114(12):1595-1604. PubMed ID: 29931148
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jul 10; 138(2):131-140. PubMed ID: 29530884
    [Abstract] [Full Text] [Related]

  • 34. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS, Kiouri E, Katsimardos A, Kotakos C.
    Atherosclerosis; 2018 Aug 10; 275():262-264. PubMed ID: 29980053
    [Abstract] [Full Text] [Related]

  • 35. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C.
    Postgrad Med; 2017 Nov 10; 129(8):801-810. PubMed ID: 28879791
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A, Jernberg T, Hagström E, Leosdottir M, Lundman P, Ueda P.
    Eur Heart J; 2020 Oct 21; 41(40):3900-3909. PubMed ID: 32072178
    [Abstract] [Full Text] [Related]

  • 38. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C, Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica M.
    Eur J Prev Cardiol; 2019 Jun 21; 26(9):930-949. PubMed ID: 30776916
    [Abstract] [Full Text] [Related]

  • 39. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
    Nastasi DR, Moxon JV, Norman R, Trollope AF, Rowbotham S, Quigley F, Jenkins J, Golledge J.
    J Vasc Surg; 2021 Apr 21; 73(4):1396-1403.e3. PubMed ID: 32891803
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 68.